GE Healthcare Expands Immuno-Diagnostics Offering Via Partnership With Telix Pharmaceuticals

General Electric Co's GE subsidiary GE Healthcare has inked a collaborative development and reseller agreement with Telix Pharmaceuticals Limited to supply immune diagnostics radiotracers.
The new agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials.
Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumors to inform and improve therapy selection.
TLX250-CDx targets the antigen, carbonic anhydrase IX (CAIX), which can be used to identify hypoxic tumors, deprived of oxygen that can correlate with disease progression and resistance to therapy, including immunotherapy.
Identifying those tumors can guide changes in care, from immune checkpoint inhibitor (ICI) monotherapy to combination treatments that overcome the hypoxic barrier.
[18F]-FLac, which Telix in-licensed in 2021, has shown promise in imaging lactate metabolism in oxygenated tumors.
High lactate in tumors could prevent ICI responses and additionally be harmful in patients receiving ICI therapies.
GE Healthcare will be responsible for the directed marketing and sales of Telix's imaging agents to pharmaceutical companies.
The agreement has an initial term of five years, subject to review and termination rights based on performance after three years.
Price Action: GE shares are trading higher by 1.64% at $68.68 in premarket on the last check Monday.